ArticleSpringerPlus2014
Administration of a second generation perfluorochemical in combination with hyperbaric oxygenation does not provide additional benefit in a model of permanent middle cerebral artery occlusion in rats.
Article in SpringerPlus, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Preclinical Validation of the Therapeutic Potential of Glasgow Oxygen Level Dependent (GOLD) Technology: a Theranostic for Acute Stroke.Translational stroke research · 2019Article
- Protecting the ischaemic penumbra as an adjunct to thrombectomy for acute stroke.Nature reviews. Neurology · 2018Review
- Long-term survival in permanent middle cerebral artery occlusion: a model of malignant stroke in rats.Scientific reports · 2016Article
- Hyperbaric oxygen therapy in experimental and clinical stroke.Medical gas researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBoth, second generation perfluorochemicals (Oxycyte®) and hyperbaric oxygen (HBO) have been shown to reduce necrotic tissue volume if administered early after experimental cerebral ischemia. With the idea of exponentiation of oxygen delivery to ischemic tissue, this study was conducted to investigate the combined effect of both treatment modalities on the extent of ischemic brain damage.
methodsPermanent focal cerebral ischemia was induced in rats by middle cerebral artery occlusion (MCAO). Animals were assigned randomly to one of the following treatment groups: Control (0.9% NaCl, 1 ml/100 g i.v.), Oxycyte® (1 ml/100 g i.v.), HBO (1 bar hyperbaric oxygenation for 1 h) and HBO + Oxycyte® (1 ml/100 g i.v. combined with 1 bar hyperbaric oxygenation for 1 h). Injection of NaCl or Oxycyte® was performed following MCAO. After injection, breathing was changed to 100% oxygen in Oxycyte®-, HBO- and HBO + Oxycyte®-groups. After eight hours the necrotic volume was calculated from serial coronal sections stained with silver-nitrate and corrected for the extent of swelling.
resultsHemodynamic and metabolic parameters were not affected by infusion of Oxycyte®. Total necrosis volume was significantly reduced in HBO-treated animals (223 ± 70 mm(3)), when compared to control animals (335 ± 36 mm(3)). In animals after Oxycyte®-treatment alone (299 ± 33 mm(3)) or combined HBO + Oxycyte®-treatment (364 ± 50 mm(3)) did not show a significantly smaller necrosis volume compared to control animals (necrosis volumes are given as mean ± SD). DISCUSSION: These results suggest that combination of hyperbaric oxygenation and Oxycyte® administered immediately after onset of vascular occlusion does not provide an additional neuroprotective effect in the early phase of brain ischemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.